Last reviewed · How we verify

Hangzhou YuYuan Bioscience Technology Co., Ltd. — Portfolio Competitive Intelligence Brief

Hangzhou YuYuan Bioscience Technology Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Follitrope PFS Follitrope PFS phase 3 Gonadotropin (recombinant FSH) FSH receptor (FSHR) Reproductive Medicine / Fertility
Gonal-f pen Gonal-f pen phase 3 Recombinant gonadotropin (FSH) FSH receptor (FSHR) Reproductive/Fertility

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. LG Life Sciences · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hangzhou YuYuan Bioscience Technology Co., Ltd.:

Cite this brief

Drug Landscape (2026). Hangzhou YuYuan Bioscience Technology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hangzhou-yuyuan-bioscience-technology-co-ltd. Accessed 2026-05-16.

Related